EU Drug Regulator Approves Use of Bavarian Nordic's mpox Vaccine, Imvanex for Adolescents

EU Drug Regulator Approves Use of Bavarian Nordic's mpox Vaccine, Imvanex for Adolescents

By, Admin 23 September 2024

Overview

Bavarian Nordic A/S, a fully integrated vaccine company with a mission to protect and save lives through innovative vaccines, announced that the European Commission has adopted the Committee for Medicinal Products for Human Use (CHMP) recommendation for the approval of a type II variation for Imvanex (MVA-BN) smallpox and mpox vaccine, extending the current marketing authorization to include adolescents 12 to 17 years of age.

MVA-BN Approval

  • MVA-BN is approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA. This is the second EMA approval of an MVA-BN-based vaccine for a younger population.
  • The decision comes after one week the WHO approved the vaccine for adults.

The CHMP Recommendations

The CHMP recommendation follows the submission last month to EMA of data from a clinical study (NCT05740982), sponsored by the US National Institutes of Health’s (NIH) National Institutes of Allergy and Infectious Diseases (NIAID), in 315 adolescents 12-17 years of age and 211 adults aged 18 years and older, demonstrating non-inferiority of the immune responses as well as a similar safety profile between both age groups after vaccination with two standard doses of the MVA-BN vaccine.

Various Approvals

  • While this represents the first approval of MVA-BN as a smallpox/mpox vaccine for adolescents, a recombinant version of MVA-BN (Mvabea) was approved by EMA in 2020 as part of a prime-boost vaccine regimen1 for the prevention of disease caused by Ebola virus in individuals =1 year of age. 
  • Clinical studies supporting this approval encompass more than 3,300 individuals across Europe, USA, and Africa including over 800 children and adolescents 1-17 years of age in Africa. 
  • The safety profile of Mvabea in children 1-17 years of age was generally similar to that observed in adults and similar to the safety profile of MVA-BN in individuals 12 years and older.

Statement from CEO: Bavarian Nordic

Paul Chaplin, president & CEO of Bavarian Nordic, said: “We applaud EMA for their expedited review and decision to recommend approval of MVA-BN for adolescents. This represents an important milestone in our efforts to make our vaccine available for all populations and will help improve access for some of the most vulnerable individuals mostly impacted by the ongoing mpox outbreak in Africa.”

Bavarian Nordic on trial

  • Bavarian Nordic is preparing for a clinical trial (NCT06549530) to assess the immunogenicity and safety of MVA-BN in children 2-12 years of age, aiming to further extend the indication of the vaccine into younger populations. 
  • The trial, partially funded by the Coalition for Epidemic Preparedness Innovations (CEPI), is expected to start next month.

About CEPI

  • CEPI has also co-funded a clinical study (NCT05745987), led by McMaster University in Canada, to assess post-exposure vaccination with MVA-BN, i.e. if the vaccine helps reduce the risk of secondary mpox cases, or, in case of mpox infection, can reduce the severity of illness. 
  • The study will include over 1.500 participants including children in households with a laboratory-confirmed mpox infection at sites in the DRC, Uganda and Nigeria. 
  • Results of the study could provide important findings to inform vaccination strategies in areas impacted by the mpox outbreak.

About Modified Vaccinia Ankara-Bavarian Nordic

  • MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic is the only non-replicating mpox vaccine approved in the US, Switzerland, Singapore and Mexico (marketed as Jynneos), Canada (marketed as Imvamune), and the EU/EAA and United Kingdom (marketed as Imvanex). 
  • Originally developed as a smallpox vaccine in collaboration with the US government to ensure the supply of a smallpox vaccine for the entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines, MVA-BN has been indicated for use in the general adult population in individuals considered at risk for smallpox or mpox infection.

The Primary Suppliers

Bavarian Nordic has been a long-term supplier of the vaccine to national stockpiles, and during the 2022-2023 mpox outbreak, the company supported governments and supranational organizations by expanding access to the vaccine to more than 70 countries worldwide.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!